Clinical Trial Search

Primary: Comparative Outcomes: Intervention Group LDL Reduction Compared to Control Group LDL Reduction — 11.0; 11.1 % of patients with major LDL reduction — p=0.99

Primary: Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke — 14.2; 20.8 percentage of annual rate of change

Primary: Predicted Annual Rate of Change in 10-year Risk of Fatal or Nonfatal Heart Attack or Stroke — -0.59; 1.66 annualized change in 10 year % cv risk — p=<0.05

Primary: Percent of Patients Achieving Hemoglobin A1C Goal, LDL Cholesterol Goal, and Systolic Blood Pressure Goal From the Enrollment Until the End of the Study — 40.8; 20.4…

Primary: Change From Baseline of Total Cholesterol After 90 Days — -0.57; -1.09 mmol/L — p=0.042

Primary: New Participation in MOVE! (Among Women Aged 65 and Older) — 1.09 Odds Ratio — p=.003

Primary: AIM 1: Change in Flow Mediated Dilation (FMD) (%) — -0.0012; 0.018; 0.014; 0.0053 percentage of arterial dilation change — p=0.943

Primary: Percentage of Participans With A1c<7%, LDL Cholesterol <100mg/dL, Systolic Blood Pressure <130mm Hg and Diastolic Blood Pressure <80 mm Hg — 40.4; 21.6; 65.5; 39.9…

Primary: Number of Subjects With Lipids Checked (Available Now Through National Laboratory Chain) or That Reported Having Their Lipids Checked by Their 1-week or 3-month Visit…

Primary: Number of Participants With Visit to a Cardiology Specialist From Cohort — 283 Participants

Primary: Low-density Lipoprotein Cholesterol — 100.1; 110.6 mg/dL — p=<0.001

Primary: Global Framingham Risk Score — 11.5; 12.7; 9.9; 12.3 score on a scale

Primary: Mean Low Density Lipid-Cholesterol (LDL-C) Levels in High and Very High Risk Cardiovascular Participants — 2.40; 1.99 mmol/L

Primary: Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its Components — 322; 320; 313; 535 Participants — p=0.0648

Primary: Reduction of the Estimated 10-year Total Cardiovascular Risk Score — 11.5; 11.1 percent

Primary: Change in LDL From Baseline to 12 Months — 27.9; 25.1; 33.6; 25.1 mg/dL

Primary: Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12 — 12.5; 16.3 percent risk — p=<0.001

Primary: Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization — 3.11; 2.74; 6.01; 5.31 percentage of…

Primary: First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in…

Primary: Major Cardiovascular Adverse Events (MACE) — 156; 118 number of adjudicated events — p=< 0.025

Primary: Ten Year Risk of Cardiovascular Disease (CVD) — 2.9 percentage of risk

Primary: LDL-C at Month 3 — 145 mg/dL — p=0.03

Primary: Change in Mean of Wall Volume of Internal Carotid Arteries — -3.52; -5.91 Other - mm^3 ( cubic millimeter )

Primary: Change From Baseline in Lipid Profile — 4.20; 3.37; -0.06 mg/dl

Primary: Major Cardiovascular Disease Event — 3182; 527 Cardiovascular disease event

Primary: Change in Blood LDL Cholesterol Level — -32.48; 2.54 mg/dL — p=<0.0001

Primary: Number of Participants With Type 2 Diabetes (T2D) Who Had Prescription Changes in Concordance With SSCVD Results — 45; 13; 8; 35 Participants

Primary: Coronary Flow Reserve — 2.65 ratio

Primary: Change in Mean Systolic and Diastolic Blood Pressure (mm/Hg) From Baseline (Time 1) to Time 2 — -0.3; -2.4; 1.2; 2.2 mmHg

Primary: Eating Habits Confidence Survey — 4.2; 4.5 units on a scale